Lotrimin AF
Executive Summary
Schering's OTC antifungal product will be available beginning in July. The 1% clotrimazole topical-liquid and cream formulations are indicated for the self-treatment of athlete's foot, jock itch and ringworm. Lotrimin AF, which will be positioned as a professional product vis a vis the consumer orientation for Tinactin, was approved Oct. 27 ("The Pink Sheet" Oct. Oct. 30, T&G-1).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.